ROIV insider sale notice: Matthew Gline reports large sales

Rockefeller Financial LLC and related parties reported proposed and recent sales of Common Stock.

Rhea-AI Filing Summary

Rockefeller Financial LLC and related parties reported proposed and recent sales of Common Stock. The excerpt lists proposed dispositions of 43,493 shares (CVAR grant, dated 03/30/2026) and 246,281 RSUs (grant dated 07/26/2024) with settlement dates in late March 2026. It also reports sales by Matthew Gline on 03/30/2026 of 53,826 shares for $1,421,544.66 and 304,684 shares for $8,439,746.80.

Insights

Equity Capital Markets Analyst

Routine resale disclosure listing proposed and completed insider share sales.

The filing lists planned dispositions tied to prior grants (a CVAR grant and RSU grant) and two completed sales by a reporting person on 03/30/2026 with precise share counts and proceeds. These entries record transfers and proceeds; they do not provide company guidance or balance-sheet changes.

Watch for subsequent filings that may disclose additional holder identities or confirm settlement mechanics; timing and cash‑flow recipients are not detailed in the excerpt.

Key Figures

Proposed CVAR-related shares: 43,493 shares Proposed RSU disposition: 246,281 RSUs Sale by Matthew Gline — lot 1: 53,826 shares +1 more

4 metrics

Proposed CVAR-related shares 43,493 shares CVAR Grant dated 03/26/2020 with disposition date 03/30/2026

Proposed RSU disposition 246,281 RSUs RSU Grant dated 07/26/2024 with disposition date 03/31/2026

Sale by Matthew Gline — lot 1 53,826 shares Sold 03/30/2026 for $1,421,544.66

Sale by Matthew Gline — lot 2 304,684 shares Sold 03/30/2026 for $8,439,746.80

Key Terms

Form 144, RSU, CVAR Grant

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

RSU financial

"RSU Grant - Grant date 07/26/2024"

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

CVAR Grant financial

"CVAR Grant - Grant Date 03/26/2020"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions does ROIV disclose in this Form 144 excerpt?

Answer: The excerpt shows proposed dispositions of 43,493 shares and 246,281 RSUs, plus two sales by Matthew Gline. It records sales on 03/30/2026 of 53,826 shares for $1,421,544.66 and 304,684 shares for $8,439,746.80.

Who reported the recent share sales in the ROIV filing?

Answer: The excerpt identifies Matthew Gline as the reporting person for the completed sales on 03/30/2026. The filer/issuer information lists Rockefeller Financial LLC in connection with the common shares listed.

Do the entries show the grant dates for the securities ROIV intends to sell?

Answer: Yes. The CVAR grant referenced carries a grant date of 03/26/2020, and the RSU grant referenced shows a grant date of 07/26/2024, with disposition dates in March 2026.

Are proceeds and per‑share prices provided for the reported ROIV sales?

Answer: The excerpt supplies aggregate proceeds for two completed sales: $1,421,544.66 (53,826 shares) and $8,439,746.80 (304,684 shares). Per‑share prices are not explicitly listed as single‑share amounts in the excerpt.

Does this Form 144 excerpt state who receives the sale proceeds for ROIV?

Answer: The excerpt provides aggregate proceeds for reported sales but does not state who receives the proceeds or the cash‑flow treatment. The filing text in the excerpt does not specify recipient details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 04:33 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001750094
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Roivant Sciences Ltd.
SEC File Number	001-40782
Address of Issuer	7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM SW1H 0DB
Phone	441-295-5950
Name of Person for Whose Account the Securities are To Be Sold	Gline Matthew
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rovkefeller Plaza Floor 5th New York NY 10111	289774	8449876.49	715701137	04/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/30/2026	CVAR Grant - Grant Date 03/26/2020	ROIV			43493	03/30/2026	n/a
Common	03/31/2026	RSU Grant - Grant date 07/26/2024	ROIV			246281	03/31/2026	n/a

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Matthew Gline 7th Floor - 50 Broadway London X0 sw1h0db	ROVI	03/30/2026	53826	1421544.66
Matthew Gline 7th Floor - 50 Broadway London X0 SW1H0DB	ROIV	03/30/2026	304684	8439746.80

144: Remarks and Signature

Remarks
Date of Notice	04/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Carmen Zamores as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Gline Matthew
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)